Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593204 | 0.88 | ROCK2 (0.50) | RAB9AROCK2IMPDH2NOTUMPRMT3 | |
| SCHEMBL3585236 | 0.84 | IMPDH2 (0.52) | RAB9AIMPDH2NOTUMPRMT3 | |
| SCHEMBL13913490 | 0.83 | SMN1; SMN2 (0.58) | RAB9ANAMPTIMPDH2 | |
| SCHEMBL3598434 | 0.83 | IMPDH2 (0.69) | ROCK2IMPDH2NOTUMPRMT3 | |
| SCHEMBL3602258 | 0.82 | IMPDH2 (0.58) | RAB9AROCK2IMPDH2NOTUMPRMT3 | |
| SCHEMBL14625937 | 0.81 | ROCK2 (0.60) | ROCK2IMPDH2NOTUMPRMT3 | |
| SCHEMBL3595348 | 0.78 | ROCK2 (0.60) | RAB9AROCK2IMPDH2NOTUMPRMT3 | |
| SCHEMBL3586989 | 0.78 | IMPDH2 (0.60) | RAB9AROCK2IMPDH2NOTUMPRMT3 | |
| SCHEMBL3593323 | 0.78 | ROCK2 (0.58) | ROCK2IMPDH2NOTUMPRMT3 | |
| SCHEMBL3588716 | 0.77 | IMPDH2 (0.70) | ROCK2IMPDH2NOTUMPRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910297-B1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-1910297-B1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20100093790-A1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20090069371-A1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-7470787-B2 | Isoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1910297-A1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070142429-A1 | Isoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2007008926-A1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069371-A1 | ISOQUINOLINE COMPOUNDS | GNAQ, GRK2, GRK3 | RAB9A 285/4885HDAC1 2491/4885NAMPT 2230/4885 |
| US-20070142429-A1 | Isoquinoline compounds | GNAQ, GRK2, GRK3 | RAB9A 285/4885HDAC1 2491/4885NAMPT 2230/4885 |
| US-20100093790-A1 | ISOQUINOLINE COMPOUNDS | GNAQ, GRK2, GRK3 | RAB9A 285/4885HDAC1 2491/4885NAMPT 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.